PureTech Health
PRTC
PRTC was delisted on the 20th of May, 2026.
4 hedge funds and large institutions have $4.9M invested in PureTech Health in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
3% more capital invested
Capital invested by funds: $4.78M → $4.9M (+$121K)
0% more funds holding
Funds holding: 4 → 4 (0)
0% less ownership
Funds ownership: 0.21% → 0.21% (-0%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$5.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $1.77M | – | – | – |
|
|
BHIA
2
Birch Hill Investment Advisors
Boston,
Massachusetts
| $1.67M | – | – | – |
|
|
CG
3
Colony Group
Boston,
Massachusetts
| $1.45M | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $7K | -$5.36K | -96 | -43% |
|
PRTC Hedge Fund Activity: Q1 2021 in Review
4 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in PureTech Health (PRTC) for Q1 2021, worth a combined $4.9M — up 2.5% from $4.78M a quarter earlier.
Fund positioning in PRTC was balanced in Q1 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $5.36K.
- 4 institutional investors held PureTech Health (PRTC) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $4.9M of PureTech Health stock for Q1 2021, up 2.5% quarter-over-quarter.
- 0 funds opened new PureTech Health positions in Q1 2021 and 0 closed out.
- The largest PureTech Health seller in Q1 2021 was UBS Group, an estimated $5.36K sold.
Based on aggregated 13F filings for Q1 2021.